Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Medical Food (Enterade) for the Reduction of Bowel Movement Frequency in Patients with Carcinoid Syndrome or Non-Carcinoid Syndrome Neuroendocrine Tumor
This phase II trial studies how well a medical food called enterade works in reducing bowel movement frequency in patients with carcinoid syndrome or non-carcinoid syndrome neuroendocrine tumor. Enterade is a commercially available amino acid-based medical food being developed to manage diarrhea due to carcinoid syndrome or other neuroendocrine tumors. It may also alleviate abdominal pain or discomfort, bloating, cramping and gas secondary to the disease. Enterade may alleviate neuroendocrine tumor associated diarrhea, provide control of bowel-related symptoms, and improve quality of life in neuroendocrine tumor patients with diarrhea.
Multiple Cancer Types
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg / m2 ± 250 mg / m2 BID (strata 1, 2, 3, and 4) OR 2500 mg / m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Endocrine, Neuroblastoma (Pediatrics), Neuroendocrine, Pediatrics